Gadi Saarony, CEO“Our unique portfolio of technology and services reduces friction by decreasing technology burden, improving study visibility, and enabling smarter decisions that advance clinical research,” says Gadi Saarony, CEO. This comprehensive portfolio includes trusted independent review bodies, cutting-edge technology platforms, and experienced consultancy offerings.
Independent review bodies, such as Institutional Review Boards (IRBs), ensure that trials meet regulatory standards and that participant risks are minimized. Federal regulations require that IRBs consist of scientific and non-scientific members tasked with reviewing study materials, including protocols, informed consent forms, investigator credentials, and safety events.
In addition to the IRB, other specialized committees, such as Institutional Biosafety Committees (IBCs) and Data Safety Monitoring Boards (DSMBs), contribute to maintaining the safety of clinical research. IBCs ensure the safety of research participants, study staff, and the community by reviewing and assessing biosafety risks associated with cell and gene therapy techniques, particularly those involving genetic modifications. Independent DSMBs are also responsible for monitoring accumulated data to identify potential risks or benefits, offering recommendations to modify or halt the trial when necessary.
Led by a team of seasoned experts with decades of experience building robust quality systems, Advarra applies industry best practices with practical, risk-based thinking to deliver customized solutions that enhance performance and ensure long-term compliance. These tailored offerings include quality management systems, good x practice (GxP) audits, and health inspection readiness and remediation, all crafted to address each client's unique needs.
Advarra also specializes in optimizing research compliance and site operations. The team collaborates with clients to navigate the complex and evolving regulatory landscape, ensuring adherence to federal regulations, state and local laws, and industry best practices. With a deep pool of expertise from R1 institutions, the team delivers tailored solutions that ensure continuous compliance and support operational efficiency across all stages of the research process.
The company offers clinical research technology solutions designed to optimize research performance, support clinical sites, and streamline processes for life science companies. Key offerings include clinical trial management software for end-to-end trial oversight, study collaboration tools to improve workflows across sites and sponsors, and study startup solutions to ensure timely milestone achievement. Tailored to meet each client's unique needs, these solutions enhance visibility and efficiency throughout the research process.
Trusted by a wide range of research sites and institutions, Advarra supports academic medical centers, cancer centers, health systems, and site networks with solutions designed to streamline processes, improve patient recruitment, and accelerate research outcomes. It enhances operational management, financial visibility, compliance, and decision-making by providing integrated, cloud-based technology solutions for clinical research sites, including OnCore CTMS, Advarra eReg, eConsent, and clinical conductor CTMS.
Advarra’s commitment to reducing barriers, enhancing transparency, and fostering collaboration is at the core of transforming clinical trial operations. By continuously driving advancements in human health, the company ensures the safe, ethical, and efficient development of life-changing therapies. This dedication to innovation is crucial in reshaping the future of clinical trials while paving the way for breakthroughs that will improve lives for future generations.
